New Report on Toxic Posterior Segment Syndrome Following Dropless Cataract Surgery with Compounded Triamcinolone-Moxifloxacin
In 2017, an unexpected cluster of patients in the Dallas area who had recently undergone dropless cataract surgery (DLCS) developed toxic posterior segment syndrome (TPSS), a rare, non-infectious inflammatory condition affecting the
read more
Recent Study Examined the Cytopathology and Prognostic Accuracy of the 15-GEP/PRAME Assay for Uveal Melanoma Metastasis
As part of the Collaborative Ocular Oncology Group (COOG), Texas Retina’s Timothy Fuller, MD, recently participated in a multi-center clinical research cohort study to determine if the results of an additional cell examination
read more Getting to Know Ocular Oncologist Timothy S. Fuller, MD
May is Ocular Melanoma Awareness Month. Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina Associates, we have
read more
May is Ocular Melanoma Awareness Month
Ocular (uveal) melanoma is a rare but dangerous disease. It involves the iris, ciliary body, and/or choroid, which are collectively referred to as the uvea, and the tumors develop in the pigmented
read more New Research on Early Genetic Evolution of Driver Mutations in Uveal Melanoma
Texas Retina’s Timothy Fuller, MD, in collaboration with and under the leadership of Dr. J. William Harbour, the Chair of the Department of Ophthalmology at UT Southwestern Medical Center, participated in a multi-center
read more Texas Retina Participating in New Phase III Clinical Trial for Uveal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina will soon begin enrolling patients in the OptimUM-10 clinical trial, a randomized, Phase III, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic
read more Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura Biosciences,
read more May is Ocular Melanoma Awareness Month
Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina, we have been caring for ocular melanoma
read more
Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more
Meet Our Dallas Clinical Research Coordinators
Karen Duignan, Sally Arceneaux, Ashley Hughes and Jessica Flores serve as our clinical research coordinators for Dallas. They assist patients with their enrollment and participation in our wide variety of clinical trials
read more